Skip to main content
Français
Search form
Search
Follow the Fraser Institute:
Contact us
About us
Our experts
Donate
Home
Research
Aboriginal Policy
Aging, Retirement, and Pensions
Competitiveness
COVID-19
Economic Freedom
Education Policy
Energy
Environment
ESG - Environmental, Social and Governance
Federal Reform Series
Gov't Spending & Taxes
Health Care
Labour Policy
Monetary Policy and Banking
Municipal Policy
Natural Resources
Poverty and Inequality
Provincial Prosperity
Realities of Socialism
School Report Cards
Essential Scholars
Other Research Topics
More from the Fraser Institute
Education Programs
Western Canada BC, AB, SK, MB, NT, YT, NU
For Students
For Teachers
For Journalists
Central Canada ON, QC, NB, NS, PE, NL
Peter Munk Centre for Free Enterprise Education
For Students
For Teachers
For Journalists
Economic Freedom
School Rankings
Blog
Events
Founders' Award
Other Events
Podcast
Women, Economic Progress, and Markets
Fraser Forum
Donate
Who was Barbara Mitchell?
drug manufacture
drug manufacture
drug manufacture
July 12, 2016
4:27PM
Strengthening Canada’s intellectual property protections for biologic medicine may save lives
Kristina M.L. Acri, née Lybecker
Biologic medicines, used to treat cancer and other maladies, are difficult and expensive to develop and manufacture.
Tags:
biologics
,
drug production
,
medicine
,
intellectual property
,
biologic medicine
,
drug manufacture
July 12, 2016
1:30AM
The Biologics Revolution in the Production of Drugs
Kristina M.L. Acri, née Lybecker
Tags:
biologics
,
drug production
,
medicine
,
intellectual property
,
biologic medicine
,
drug manufacture
